Drugs / LX109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06022744 | Sep 2023 → Sep 2025 overdue | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022744 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LX109 Gene Therapy” NCT06022744 ↗ |
| Route | Intravitreal | “Administration route: intravitreal injection” NCT06022744 ↗ |